MREO insider transaction filings
Mereo BioPharma Group plc — 26 most recent Form 4 filings from SEC EDGAR, normalized by FilingPulse. Latest filing: 2026-02-27. Screen MREO transaction legs live →
| Filed | Form | Insider | Reported transactions | Source |
|---|---|---|---|---|
| 2026-02-27 | 4 | Jacquet Pierre — Director | Grant/award (A): 66,000 (derivative) @ $0 · Grant/award (A): 106,848 (derivative) | EDGAR |
| 2026-02-27 | 4 | Bender Jeremy — Director | Grant/award (A): 66,000 (derivative) @ $0 · Grant/award (A): 117,533 (derivative) | EDGAR |
| 2026-02-27 | 4 | Shames Daniel — Director | Grant/award (A): 66,000 (derivative) @ $0 · Grant/award (A): 96,163 (derivative) | EDGAR |
| 2026-02-27 | 4 | Ekblom Anders — Director | Grant/award (A): 66,000 (derivative) @ $0 · Grant/award (A): 133,560 (derivative) | EDGAR |
| 2026-02-27 | 4 | Jenkins Annalisa — Director | Grant/award (A): 66,000 (derivative) @ $0 · Grant/award (A): 106,848 (derivative) | EDGAR |
| 2026-02-27 | 4 | Yoskowitz Marc J — Director | Grant/award (A): 66,000 (derivative) @ $0 · Grant/award (A): 96,163 (derivative) | EDGAR |
| 2026-02-27 | 4 | PAKIANATHAN DEEPIKA — Director | Grant/award (A): 66,000 (derivative) @ $0 | EDGAR |
| 2026-02-27 | 4 | WYZGA MICHAEL S — Director | Grant/award (A): 66,000 (derivative) @ $0 | EDGAR |
| 2026-02-02 | 4 | Hughes-Wilson Alexandra — See Remarks | Grant/award (A): 183,750 (derivative) @ $0 · Grant/award (A): 61,250 (derivative) @ $0 · Grant/award (A): 195,000 (derivative) @ $0 | EDGAR |
| 2026-02-02 | 4 | Fox Christine Ann — Chief Financial Officer | Grant/award (A): 315,750 (derivative) @ $0 · Grant/award (A): 105,250 (derivative) @ $0 · Grant/award (A): 280,000 (derivative) @ $0 | EDGAR |
| 2026-02-02 | 4 | Sermon Charles — General Counsel | Grant/award (A): 315,750 (derivative) @ $0 · Grant/award (A): 105,250 (derivative) @ $0 · Grant/award (A): 295,000 (derivative) @ $0 | EDGAR |
| 2026-02-02 | 4 | Lewicki John A. — Chief Scientific Officer | Grant/award (A): 139,913 (derivative) @ $0 · Grant/award (A): 46,637 (derivative) @ $0 · Grant/award (A): 145,000 (derivative) @ $0 | EDGAR |
| 2026-02-02 | 4 | Scots-Knight Denise — Chief Executive Officer, Director | Grant/award (A): 1,035,000 (derivative) @ $0 · Grant/award (A): 345,000 (derivative) @ $0 · Grant/award (A): 480,000 (derivative) @ $0 | EDGAR |
| 2025-02-06 | 4 | Bender Jeremy — Director | Grant/award (A): 55,000 (derivative) @ $0 · Grant/award (A): 16,768 (derivative) | EDGAR |
| 2025-02-06 | 4 | Shames Daniel — Director | Grant/award (A): 55,000 (derivative) @ $0 · Grant/award (A): 13,719 (derivative) | EDGAR |
| 2025-02-06 | 4 | Jacquet Pierre — Director | Grant/award (A): 55,000 (derivative) @ $0 · Grant/award (A): 15,243 (derivative) | EDGAR |
| 2025-02-06 | 4 | Ekblom Anders — Director | Grant/award (A): 55,000 (derivative) @ $0 · Grant/award (A): 19,054 (derivative) | EDGAR |
| 2025-02-06 | 4 | Jenkins Annalisa — Director | Grant/award (A): 55,000 (derivative) @ $0 · Grant/award (A): 15,243 (derivative) | EDGAR |
| 2025-02-06 | 4 | Yoskowitz Marc J — Director | Grant/award (A): 55,000 (derivative) @ $0 · Grant/award (A): 13,719 (derivative) | EDGAR |
| 2025-02-06 | 4 | PAKIANATHAN DEEPIKA — Director | Grant/award (A): 55,000 (derivative) @ $0 | EDGAR |
| 2025-02-06 | 4 | WYZGA MICHAEL S — Director | Grant/award (A): 55,000 (derivative) @ $0 · Grant/award (A): 30,487 (derivative) | EDGAR |
| 2025-01-28 | 4 | Fox Christine Ann — Chief Financial Officer | Grant/award (A): 262,000 (derivative) @ $0 | EDGAR |
| 2025-01-28 | 4 | Hughes-Wilson Alexandra — See Remarks | Grant/award (A): 154,000 (derivative) @ $0 | EDGAR |
| 2025-01-28 | 4 | Sermon Charles — General Counsel | Grant/award (A): 262,000 (derivative) @ $0 | EDGAR |
| 2025-01-28 | 4 | Lewicki John A. — Chief Scientific Officer | Grant/award (A): 116,000 (derivative) @ $0 | EDGAR |
| 2025-01-28 | 4 | Scots-Knight Denise — Chief Executive Officer | Grant/award (A): 825,000 (derivative) @ $0 | EDGAR |
Recent 8-K events — Mereo BioPharma Group plc
| Filed | Form | Items reported | Source |
|---|---|---|---|
| 2026-08-19 | 8-K | 3.01 — Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing | EDGAR |
| 2026-08-11 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-08-11 | 8-K | 1.01 — Entry into a Material Definitive Agreement 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-05-14 | 8-K | 5.07 — Submission of Matters to a Vote of Security Holders 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-05-12 | 8-K | 2.01 — Completion of Acquisition or Disposition of Assets 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-05-12 | 8-K/A | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-03-27 | 8-K | 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | EDGAR |
| 2026-03-19 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-02-17 | 8-K | 3.01 — Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing | EDGAR |
| 2026-01-12 | 8-K | 7.01 — Regulation FD Disclosure 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?ticker=MREO returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new ones to you in seconds. API docs →